Catalent (NYSE:CTLT) Rating Increased to Outperform at Robert W. Baird

Catalent (NYSE:CTLT) was upgraded by investment analysts at Robert W. Baird from a “neutral” rating to an “outperform” rating in a report issued on Thursday, MarketBeat.com reports. The brokerage presently has a $53.00 price target on the stock, up from their previous price target of $45.00. Robert W. Baird’s target price would suggest a potential upside of 32.93% from the stock’s current price.

A number of other equities analysts also recently commented on CTLT. Wells Fargo & Company assumed coverage on shares of Catalent in a research note on Thursday, July 20th. They issued an “equal weight” rating and a $43.00 price objective for the company. Argus raised Catalent from a “hold” rating to a “buy” rating and set a $62.00 price objective on the stock in a research report on Tuesday, September 5th. William Blair reiterated a “market perform” rating on shares of Catalent in a research note on Tuesday. StockNews.com raised shares of Catalent to a “sell” rating in a research report on Friday, November 3rd. Finally, Morgan Stanley lifted their price objective on shares of Catalent from $52.00 to $55.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 30th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $50.45.

Catalent Price Performance

CTLT opened at $39.87 on Thursday. The company has a market capitalization of $7.19 billion, a price-to-earnings ratio of -7.61, a PEG ratio of 3.62 and a beta of 1.26. The company has a current ratio of 1.71, a quick ratio of 1.27 and a debt-to-equity ratio of 1.11. Catalent has a 12-month low of $31.45 and a 12-month high of $74.49. The business’s fifty day simple moving average is $42.25 and its 200-day simple moving average is $42.99.

Catalent (NYSE:CTLT) last issued its earnings results on Wednesday, November 15th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.04. The company had revenue of $982.00 million for the quarter, compared to analysts’ expectations of $939.62 million. Catalent had a negative net margin of 22.36% and a positive return on equity of 1.54%. The firm’s quarterly revenue was down 3.9% on a year-over-year basis. During the same period in the prior year, the business earned $0.25 EPS. On average, equities research analysts anticipate that Catalent will post 0.61 earnings per share for the current fiscal year.

Insider Transactions at Catalent

In other news, insider John J. Greisch bought 21,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 30th. The shares were purchased at an average cost of $50.24 per share, with a total value of $1,055,040.00. Following the transaction, the insider now directly owns 34,000 shares in the company, valued at $1,708,160. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other Catalent news, CEO Alessandro Maselli sold 2,071 shares of Catalent stock in a transaction that occurred on Thursday, August 24th. The shares were sold at an average price of $44.54, for a total transaction of $92,242.34. Following the completion of the sale, the chief executive officer now directly owns 88,004 shares in the company, valued at approximately $3,919,698.16. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider John J. Greisch acquired 21,000 shares of the business’s stock in a transaction dated Wednesday, August 30th. The stock was acquired at an average price of $50.24 per share, for a total transaction of $1,055,040.00. Following the purchase, the insider now directly owns 34,000 shares of the company’s stock, valued at $1,708,160. The disclosure for this purchase can be found here. Over the last ninety days, insiders sold 3,553 shares of company stock worth $158,329. Company insiders own 0.58% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CTLT. Barclays PLC lifted its holdings in shares of Catalent by 578.0% in the 2nd quarter. Barclays PLC now owns 3,385,660 shares of the company’s stock valued at $146,802,000 after buying an additional 2,886,309 shares during the period. Cadian Capital Management LP purchased a new stake in Catalent in the 2nd quarter worth approximately $120,456,000. Capital World Investors grew its stake in shares of Catalent by 19.1% during the 2nd quarter. Capital World Investors now owns 15,960,335 shares of the company’s stock worth $692,040,000 after purchasing an additional 2,556,699 shares during the period. Castle Hook Partners LP purchased a new position in shares of Catalent during the 2nd quarter valued at approximately $74,987,000. Finally, Senator Investment Group LP acquired a new position in shares of Catalent in the 1st quarter valued at $98,565,000.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.